Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation: Cardiovascular Imaging
Search: search_blue_button Advanced Search
Circulation: Cardiovascular Imaging. 2008;1:220-226
Published online before print September 17, 2008, doi: 10.1161/CIRCIMAGING.108.787358
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1/3/220    most recent
CIRCIMAGING.108.787358v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Turner, G. H.
Right arrow Articles by Jucker, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Turner, G. H.
Right arrow Articles by Jucker, B. M.
Related Collections
Right arrow Animal models of human disease
Right arrow Imaging
Right arrow Other Vascular biology
Right arrow Other Research

Original Articles

In Vivo Serial Assessment of Aortic Aneurysm Formation in Apolipoprotein E–Deficient Mice via MRI

Gregory H. Turner, PhD; Alan R. Olzinski, MS; Roberta E. Bernard, BS; Karpagam Aravindhan, PhD; Heather W. Karr, BS; Rosanna C. Mirabile, MS; Robert N. Willette, PhD; Peter J. Gough, PhD and Beat M. Jucker, PhD

From the Cardiovascular and Urogenital Center of Excellence for Drug Discovery (G.H.T., A.R.O., R.E.B., K.A., H.W.K., R.N.W., P.J.G., B.M.J.), and Safety Assessment (R.C.M.), GlaxoSmithKline, King of Prussia, Pa.

Correspondence to Beat M. Jucker, PhD, GlaxoSmithKline, 709 Swedeland Rd, King of Prussia, PA 19406. E-mail beat.m.jucker{at}gsk.com

Received April 22, 2008; accepted September 5, 2008.

Background— Hyperlipidimic mice administered angiotensin II have been used for the study of abdominal aortic aneurysms (AAAs). The purpose of this study was to examine the use of MRI for studying AAA development and for examining the effects of pharmacological intervention on AAA development in the apolipoprotein E–deficient mouse.

Methods and Results— Suprarenal aortic aneurysms were generated in apolipoprotein E–deficient mice administered angiotensin II (1000 ng/kg per min) for up to 28 days. In vivo MRI was performed serially (once weekly) to assess AAA development and rupture. Comparison of AAA size as measured by in vivo and ex vivo MRI resulted in excellent agreement (r=0.96, P<0.0001). In addition, MRI correlated with histology-derived AAA area assessment (in vivo versus histology: r=0.84, P<0.0001; ex vivo versus histology: r=0.89, P<0.0001). In a separate study, angiotensin II–administered apolipoprotein E–deficient mice were treated with doxycycline (broad-based matrix metalloproteinase inhibitor; 30 mg/kg per day for 28 days). MRI was able to noninvasively assess a reduced rate of AAA development (46% versus 71%, P<0.05), a decreased AAA area (2.56 versus 4.02 mm2, P<0.01), and decreased incidence of rupture (43% versus 100%) in treated versus control animals. Inhibition of aorta matrix metalloproteinase 2/9 activity was observed in the treated animals.

Conclusions— These results demonstrate the use of MRI to noninvasively and temporally assess AAA development on pharmacological intervention in this preclinical cardiovascular disease model.

Key Words: abdominal aortic aneurysms • imaging • MRI • doxycycline • MMP